A couple of years ago I was listening to an early stage drug hunter expert talk about how they were going to do things differently in building their oncology pipeline.

Simulations galore!

At the time, they had no official targets announced and much of the noise and attention was on the filling of seats on the Board or leading positions in the company, so very early days indeed.

The following year heralded an IPO, dosing of the initial patient in their inaugural clinical trial and just a few months later, their very first licensing deal and collaboration with a large Pharma company, so clearly a young biotech company going places.

What’s happened since and what so different or special about their approach to cancer drug development?

It turns out there were some surprises in store and some very cool science behind it…

BSB subscribers can learn more about our latest interview in the AI/deep learning niche – you can read all about it by logging in or click to access our ongoing oncology coverage.

This content is restricted to subscribers

Posted by